CRISPR-based mutation detection using graphene chip enables cancer detection
| Reference number | |
| Coordinator | Chalmers Tekniska Högskola AB - Biology and Biological Engineering - Systems and Synthetic Biology |
| Funding from Vinnova | SEK 2 998 492 |
| Project duration | May 2021 - May 2023 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Project that contributes to improved prevention, diagnosis, monitoring or treatment |
Important results from the project
The objective of this project was to engineer a graphene-based sensor for detection of circulating tumor DNAs (ctDNAs) based on graphene functionalization with Cas9-sgRNA. We produced a prototype sensor chip based on graphene functionalized with Cas9-sgRNA. The sensor is capable of detecting 1 ng/ml of KRAS ctDNA, with linear response up to 50 ng/ml, and single nucleotide mutation specificity.
Expected long term effects
The sensor sensor for KRAS ctDNA is meeting all technical performance milestones specified by the Sahlgrenska University Hospital. The technology demonstrator is being shown to key stakeholders. We are preparing project results for publication, while in parallel assessing potential for intellectual property protection.
Approach and implementation
ctDNA sequences relevant for detection of KRAS have been selected by the hospital partner from the Cancer Research Center, Sahlgrenska university Hospital. Graphene functionalization with Cas9-sgRNA has been performed and optimized at Chalmers. A micro-SD USB-based sensor device was produced as a prototype/demonstrator and tested on relevant biological samples provided by the hospital partner. Tight collaboration between Chalmers and Sahlgrenska was essential for reaching project goals.